Congratulations to the entire team of Numab Therapeutics! Numab has established its proprietary antibody technology platform and validated it through collaborations with several biopharma partners. In 2021, HBM and Novo led Numab‘s first large institutional financing round, joined by Forbion and other international investors.
Numab is thrilled to announce that Johnson & Johnson has entered into a definitive agreement to acquire Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab that holds the rights to NM26. NM26 is an investigational first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis, discovered and engineered through Numab’s proprietary MATCH™ technology platform. Johnson & Johnson will pay a purchase price of $1.25 billion and will gain the full rights to develop, manufacture and commercialize NM26 globally for atopic dermatitis and follow-on indications. This acquisition further validates our discovery and engineering platform and its potential to bring novel multi-specific antibodies to underserved patient populations. To learn more, please read our press release: https://lnkd.in/daWRtKVR